Dacomitinib (PF299804)
|
|
|
- CAS-Nr.
- 1110813-31-4
- Englisch Name:
- Dacomitinib (PF299804)
- Synonyma:
- Dacomitinib;PF299804;(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Dacomitinib (PF299804, PF299);(E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide;PF299;CS-168;Dachtini;Dakotinib;dacatinib;Dacotinib
- CBNumber:
- CB22566418
- Summenformel:
- C24H25ClFN5O2
- Molgewicht:
- 469.94
- MOL-Datei:
- 1110813-31-4.mol
|
Dacomitinib (PF299804) Eigenschaften
- Schmelzpunkt:
- 184-187°C
- Siedepunkt:
- 665.7±55.0 °C(Predicted)
- Dichte
- 1.344
- storage temp.
- Refrigerator
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly, Heated)
- Aggregatzustand
- White solid.
- pka
- 12.05±0.43(Predicted)
- Farbe
- White to Pale Yellow
- InChIKey
- LVXJQMNHJWSHET-AATRIKPKSA-N
- SMILES
- C(NC1C(OC)=CC2C(C=1)=C(NC1=CC=C(F)C(Cl)=C1)N=CN=2)(=O)/C=C/CN1CCCCC1
- CAS Datenbank
- 1110813-31-4
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| WGK Germany |
WGK 3 |
|
|
| HS Code |
29335990 |
|
|
| Speicherklasse |
11 - Combustible Solids |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Dacomitinib (PF299804) Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
The epidermal growth factor receptors (EGFR), whose members include ErbB1 (HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4), are receptor tyrosine kinases that are often over-
expressed in cancer. PF-299804 is a second generation pan-
ErbB receptor tyrosine kinase inhibitor (IC
50s = 6, 45.7, and 73.7 nM for ErbB1, ErbB2, and ErbB4, respectively) that irreversibly binds to the ATP site in the catalytic domains of ErbB receptors. At 15 mg/kg, it demonstrates antitumor activity ranging from delay in tumor growth to complete regression in various tumor xenograft models expressing either wild-
type ErbB or mutant ErbB family members that show resistance to first generation ErbB kinase inhibitors.
Verwenden
PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.
Definition
ChEBI: A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin
1-yl)but-2-enoyl group.
Trademarks
Vizimpro
TM
Dacomitinib (PF299804) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Dacomitinib (PF299804) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 391)Lieferanten
1110813-31-4()Verwandte Suche:
- PF-00299804-03
- PF-00299804
- DacoMitinib (PF-00299804)
- DacoMitinib,PF299804
- DacoMitinib (PF299804,PF-00299804)
- PF299804;DACOMITINIB
- DacoMitinib (PF299804, PF299)
- (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquizolin-6-yl)-4-(piperidin-1-yl)but-2-eMide
- dacomitinib (pan-HER inhibitor)
- (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
- Dacomitinib, >=98%
- 2-Butenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-
- PF299
- PF299804;(E)-N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXYQUINAZOLIN-6-YL)-4-(PIPERIDIN-1-YL)BUT-2-ENAMIDE
- (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
- PF299804 (Dacomitinib, PF299)
- PF299804, PF299)
- PF-299804 (Dacomitinib,PF-00299804)
- CS-168
- PF299804; DACOMITINIB; PF-00299804;PF-299804;PF 299804
- Dacomitinib, 98%, a potent irreversible ErbB inbibitor
- Dacomitinib (USAN/INN)
- Dacomitinib [USAN]
- Dacomitinib Dacomitinib
- Dacomitinib-D10
- Dacomitinib (PF299804) USP/EP/BP
- Dacomitinib dihydrochloride salt
- Dacomitinib D10 dihydrochlorideQ: What is
Dacomitinib D10 dihydrochloride Q: What is the CAS Number of
Dacomitinib D10 dihydrochloride
- Dacomitinib D3
- Dacomitinib D5
- (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
- Dachtini
- Dacomitinib free base
- Dacomitinib / PF 00299804-03
- Dakotinib
- dacatinib
- Dacotinib
- Dacomitinib, 10 mM in DMSO
- D10-Dacomitinib dihydrochloride
- (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Dacomitinib (PF299804, PF299)
- PF299804
- Dacomitinib
- 1110813-31-4
- C24H25ClFN5O2
- Inhibitors
- Anti-cancer&immunity
- API
- API
- 1
- APIs
